A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

The Trump administration's plan to cut funding for HIV vaccine research comes at a time when the field is making substantial ...

In a sweeping national overhaul of HIV prevention funding, the CDC chose to bypass local and statewide community ...

She added that CSOs are crucial in pushing for government and private sector involvement. “They are the voice for the ...

Gene therapy may be a crucial tool to put HIV to sleep permanently, providing a lasting and durable treatment against the v ...

Drawing from 19 studies across sub-Saharan Africa and select global contexts, the review finds that RHIS remain largely ...

Oil prices jumped on Monday to their highest since January as the United States' weekend move to join Israel in attacking ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, maker Gilead Sciences announced Wednesday. It's the ...

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug Administration to be used to prevent HIV.

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...